2298
Placebo-controlled clinical trials of recombinant human interleukin-11 (rhIL-11, also known as oprelvekin [Neumega]) in patients with nonmyeloid malignancies have demonstrated significant efficacy in preventing postchemotherapy platelet nadirs of < or = 20,000/microL, and reducing the need for platelet transfusions while continuing chemotherapy without dose reductions.
 ( potential therapeutic event: preventing ,  patients with nonmyeloid malignancies: Subject, nonmyeloid malignancies: Subject.Disorder, recombinant human interleukin-11 (rhIL-11, also known as oprelvekin [Neumega]): Treatment, postchemotherapy platelet nadirs of < or = 20,000/microL: Treatment.Disorder, recombinant human interleukin-11: Treatment.Drug) 
Locate the role in the text that participated in the event based on the event type and return it in the event list. 
 Option: Event type: adverse event,potential therapeutic event, Arguments type: Treatment.Disorder,Treatment.Time_elapsed,Treatment.Dosage,Subject.Race,Treatment.Drug,Treatment.Route,Subject.Disorder,Treatment.Freq,Treatment,Effect,Subject.Population,Treatment.Duration,Combination.Drug,Subject,Subject.Age,Subject.Gender. 
Text: {0} 
Answer:
 ( potential therapeutic event: preventing ,  patients with nonmyeloid malignancies: Subject, nonmyeloid malignancies: Subject.Disorder, recombinant human interleukin-11 (rhIL-11, also known as oprelvekin [Neumega]): Treatment, postchemotherapy platelet nadirs of < or = 20,000/microL: Treatment.Disorder, recombinant human interleukin-11: Treatment.Drug) 